How Has The Retinal Biologics Market Size Evolved Historically?
The retinal biologics market has seen considerable growth due to a variety of factors.
•The market size of retinal biologics has seen considerable expansion in the past few years. The expected growth is from $25.17 billion in 2024 to $28.42 billion in 2025, marking a compound annual growth rate (CAGR) of 12.9%.
The augmentation during the historic period can be credited to the escalated occurrence of retinal diseases, the growing elderly population, increased awareness and early detection, developments in healthcare infrastructure, and a rise in healthcare spending.
What Will Be The Retinal Biologics Market Size In The Future?
The retinal biologics market is expected to maintain its strong growth trajectory in upcoming years.
• Over the forthcoming years, the retinal biologics market size is forecasted to experience substantial growth, eventually reaching a value of $44.51 billion by the year 2029, with an impressive compound annual growth rate (CAGR) of 11.9%.
The rise during the projected period can be credited to factors such as burgeoning therapeutic applications, enhancements in personalized medicine, growth in emerging markets, a robust pipeline of biologics and a surge in collaborations and partnerships, along with government initiatives and support. Key trends that will likely dominate the forecast period comprise non-invasive delivery methods, the application of real-world evidence, broadened indications, expedited regulatory pathways, and a focus on patient-centric outcomes.
What Are The Key Drivers Fueling Growth In The Retinal Biologics Market?
The retinal biologics market is expected to expand due to the rising incidence of diabetic eye disease. This diabetes complication, which can result in vision loss and blindness, can potentially be treated more effectively and accurately using retinal biologics, allowing for early intervention and better results in preventing vision loss. For instance, data from December 2023 showed a significant increase in diabetes prevalence in Australia, with the Australian Bureau of Statistics, a government agency, reporting a rise from 3.3% to 5.3% in 2022, equating to around 1.3 million people. As such, the advancing incidence of diabetic eye disease is spurring the growth of the retinal biologics market.
What Are The Principal Market Segments In The Global Retinal Biologics Industry?
The retinal biologics market covered in this report is segmented –
1) By Drug Class: Vascular Endothelial Growth Factor (VEGF)-A Antagonist, Tumor Necrosis Factor (TNF)-A Inhibitor
2) By Indication: Macular Degeneration, Diabetic Retinopathy, Uveitis, Diabetic Macular Edema, Other Indications
3) By Distribution Channel: Hospitals, Pharmacies, Specialty Clinics, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Vascular Endothelial Growth Factor (VEGF)-A Antagonist: Monoclonal Antibodies, Small Molecule Inhibitors
2) By Tumor Necrosis Factor (TNF)-A Inhibitor: Monoclonal Antibodies, Fusion Proteins
Pre-Book The Retinal Biologics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Retinal Biologics Sector?
In the retinal biologics market, a leading trend is the focus on product innovation. Many of the top firms in the market are concentrating their efforts on creating unique products in a bid to consolidate their market position and secure a competitive edge. For instance, F. Hoffmann-La Roche Ltd., a healthcare firm based in Switzerland, revealed in May 2023 that its supplemental biologics license application (sBLA) for Vabysmo (faricimab), intended for treating macular edema following retinal vein occlusion (RVO), had been approved by the U.S. Food and Drug Administration. The sanction came after two Phase III trials demonstrated the product's early and persistent success in improving vision, matching the key goal of non-inferiority to aflibercept. Vabysmo is the first bispecific antibody approved for eye application in the treatment of neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema. Additional research indicated that Vabysmo users experienced no retinal blood vessel leakage, unlike those treated with aflibercept.
Who Are the Key Players in the Retinal Biologics Market?
Major companies operating in the retinal biologics market include:
• Regeneron Pharmaceuticals Inc.
• AbbVie Inc.
• MeiraGTx Limited
• Oxurion NV
• Novartis AG
• Amgen Inc.
• Spark Therapeutics Inc.
• Bayer AG
• Bausch Health Companies Inc.
• Merck & Co. Inc.
• Santen Pharmaceutical Co. Ltd.
• Pfizer Inc.
• Boehringer Ingelheim
• Eyenovia Inc.
• EyePoint Pharmaceuticals Inc.
• Iveric Bio Inc.
• Kodiak Sciences Inc.
• Aerie Pharmaceuticals Inc.
• Alimera Sciences Inc.
• Ocular Therapeutix Inc.
• Acucela Inc.
• Clearside Biomedical Inc.
• Ophthotech Corporation
• Xcovery Holdings
• Athenex Inc.
• Fidia Farmaceutici S.p.A
• Eton Pharmaceuticals Inc.
What are the Regional Insights into the Retinal Biologics Market?
North America was the largest region in the retinal biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
